Kornimate/medical-research-clean huggingface dataset:
efhs messaging trial

Conditions: Cardiovascular Diseases

Summary: in this research the investigators will develop and test an innovative scalable mobile health and digital cardiovascular monitoring system within a longitudinal deeply characterized cohort with three components: 1) smartphone application (app) designed to promote adherence, integrate digital and mhealth information, and facilitate communication with participants and researchers; 2) smartwatch activity monitoring using the apple iwatch; and 3) home blood pressure (bp) monitoring using the withings blood pressure device. the objective of the messaging trial is to test the effect of messaging strategies on improving participants' long-term use of and engagement with our selected mobile health technologies and on increasing response rate of survey data collection.

the research design includes a cohort efhs study and an embedded randomized factorial trial on a subset of the cohort. for the primary e-cohort, the investigators will build a custom mobile app for use within the framingham heart study (fhs) to digitally collect data, compare it against research clinic-collected data, quantify risk factor burden, and perform cvd risk prediction. the app development will focus on 1) cvd risk factor data that would benefit from more frequent ascertainment than the every four to eight year fhs examination cycles; 2) circumstances where in vivo assessment may be superior to clinic-based assessment; 3) key endpoints of the fhs that are considered fhs landmarks. in addition to the efhs app, participants will be offered wireless devices (withings bp) to measure blood pressure and an apple watch to measure heart rate and steps per day. for the messaging trial, the investigators will conduct a randomized factorial trial phase to test the effect of messaging strategies. participants will be sent a weekly notification through the efhs app. participants will be randomly allocated to one of 8 groups defined according to the following: using personalized reminder messaging vs. standard neutral messaging; notification sent on a weekday vs. weekend; notification sent in the morning vs. the evening. the three main comparisons will be simultaneously evaluated according to a 2x2x2 factorial design.

Eligibility criteria:
inclusion criteria for the efhs study: * participants of the fhs third generation, omni group 2, and new offspring spouse cohorts attending the in-person examination 3 with access to a smartphone or home internet access and english speaking/reading. specifically for the rct substudy (re: engagement with select mobile health technologies): * english-speaking individual * owns an iphone with compatible ios (version 9 or higher); * residence in the united states * provision of permissions for notifications and data sharing with the research center * provision of signed and dated informed consent exclusion criteria: * participants who do not meet the inclusion criteria

Keywords: mhealth digital bp monitoring patient provider communication smart watch user engagement population health data
epidemiological screening of psychiatric disorders among school aged children and adolescent in assiut governorate

Conditions: Child Behavior Disorders; Child Mental Disorder; Adolescent Behaviour

Summary: paediatric behavioural, developmental, and mental health issues are more common than childhood cancers, cardiac problems, and renal problems combined. behavioural problems have often been conceptualized along two broad spectrums: internalizing problems which are expressed in intrapersonal manifestation, such as anxiety, depression, and withdrawal; and externalizing problems which are demonstrated in interpersonal manifestation, such as hyperactivity and aggression the lack of attention to the mental health of children and adolescents may lead to mental disorders with lifelong consequences, undermines compliance with health regimens, and reduces the capacity of societies to be safe and productive. as, children and adolescent mental health problems often have serious long term debilitating effects . early identification and treatment of these problems are in the best interest of children, adolescents, their families, and society as a whole . all three essential ways in which epidemiology can contribute to our understanding of children and adolescent mental health: community burden, measurement, and triage were of utmost importance. planning and conducting the survey. in this study the researchers will present the first large-scale survey of child and adolescent psychiatric disorders at assiut government for adequate planning of services, including evidence-based mental health prevention and intervention, a population-representative survey of children and adolescent estimating mental disorders was urgently needed


Eligibility criteria:
inclusion criteria: 1. age of children (6-18 years) 2. both males and females. 3. have education in school at assiut government. exclusion criteria: 1- unwilling parent to recruited in the study.

Keywords: child adolescent psychiatry
comparison of dermatoscopy x400 interpreted by 6 non-dermatologists and an artificial intelligence software skin artificial intelligence versus dermatoscopy x 20

Conditions: Genital Tumor; Pigmented Lesions

Summary: pigmented lesions of the genital mucosa are common, affecting between 10% and 20% of the population. the clinical appearance is sometimes confusing. they are often extensive, irregular, and inhomogeneous in color, which can make them look suspicious. moreover, dermatoscopic imaging is often complex to interpret, as shown by the many different patterns reported in the literature. thus, preliminary work in confocal microscopy has shown that it is possible to simplify diagnosis by using microscopic, in vivo, non-invasive imaging. however, cim cameras are rare, very expensive and difficult to access. conversely, digital dermatoscopes with 400x magnification are much less expensive and can also allow, in a certain number of cases, an examination at the cellular level of tumors, with, in our opinion, the advantage of being easy to learn. in the context of the pooling of resources within medical centers in particular, their dissemination should accelerate. furthermore, x400 dermatoscopy can provide similar information to ivcm for the most frequent black genital tumors.

the hypothesis that motivates this work is that x400 dermatoscopy in the hands of non-experts would allow a fast increase in their diagnostic capacity by identifying the main genital pigmented tumor, namely melanosis, and thus improve the use of expert centers relieved of the care of benign tumors.

Eligibility criteria:
inclusion criteria: * men and women with a pigmented lesion of the genital mucosa, having benefited from a mucosal consultation at the university hospital of saint-etienne, with professor perrot. * the patient's clinical file must contain clinical images, dermatoscopy images x 20 and at least 1 dermatoscopy image x 400. exclusion criteria: - none

Keywords: dermoscopy non-invasive imaging melanotic macule melanoses mucosa melanoma vulva glans tumor genital tumor nevus
prospective cohort study to describe the clinical characteristics of covid-19, the acquired immune response and the biological and clinical parameters of patients followed in oncology by the saint-joseph hospital group for a period of 6 months during the covid-19 pandemic

Conditions: Oncology; COVID-19

Summary: this registry will allow to evaluate the correlation of the incidence and evolution of associated symptoms of infection of covid-19 with the biological and clinical parameters in patients followed in oncology during the covid-19 pandemic.

prior to conducting any of the screening tests, the investigator or his designee will explain the trial fully to the prospective patient and provide him with a copy of the patient information leaflet/informed consent form. if the patient is willing to participate to the trial, his given oral, free, informed and express consent will be collected and traced in his medical file. the screening questionnaire will be completed. the patient's suitability for the trial will be confirmed by the inclusion/exclusion criteria . following completion of the baseline questionnaire, patients will receive the daily questionnaire. this is designed to assess if they have developed symptoms associated with covid-19 infection. if a participant responds that they are not feeling well, a series of follow-up questions will be asked regarding what symptoms they are currently experiencing. the daily questionnaire will be asked of patients every day throughout the observation period of 6 months. at the end of the observation period, all patients will complete a series of questionnaires relating to the conduct of the study and tools employed.

Eligibility criteria:
inclusion criteria: * patient over 18 years of age * patient followed in the medical oncology department of paris saint-joseph hospital paris in france * patient having regular access to smartphone and internet sufficient to support study demands * french-speaking patient * affiliation to the social security network * willing and able to provide given oral, free, informed and express consent exclusion criteria: * patients unable or unwilling to perform all requested study tasks * patient under tutorship or curatorship * patient deprived of liberty * pregnant or lactating patient
allogeneic sct of cordin™, in patients with hemoglobinopathies

Conditions: Sickle Cell Disease; Thalassemia

Summary: cordin™ is a cryopreserved stem/progenitor cell-based product of purified cd133+ cells composed of ex vivo expanded allogeneic ucb cells. the overall study objectives are to evaluate the safety and efficacy of cordin™.

cordin™ is a cryopreserved stem/progenitor cell-based product of purified cd133+ cells composed of ex vivo expanded allogeneic ucb cells. the trial ends when the last patient completes their last visit. the overall study objectives are to evaluate the safety and efficacy of cordin™: single ex-vivo expanded cord blood unit transplantation in patients with hemoglobinopathies (sickle cell disease or thalassemia major) following a preparative therapy.

Eligibility criteria:
inclusion criteria: * patient is a candidate for allogeneic sct for treatment of scd or thalassemia * patients must have one partially hla-matched cbus * adequate karnofsky performance score or lansky play-performance scale * sufficient physiological reserves * signed written informed consent exclusion criteria: * prior allogeneic hsct * evidence of hiv infection or hiv positive serology * evidence of active hepatitis b, hepatitis c or ebv as determined by serology or pcr * active or uncontrolled infection * pregnancy or lactation
study of glpg1837 in subjects with cystic fibrosis (s1251n mutation)

Conditions: Cystic Fibrosis

Summary: at least 6 cystic fibrosis patients with the s1251n mutation will be treated for 4 weeks, consisting of two consecutive treatment periods of two weeks evaluating one dose of glpg1837 each. after the treatment period, there is a 7-10 days follow-up period. during the course of the study, subjects will be examined for any side effects that may occur (safety and tolerability). changes in sweat chloride will be assessed as biomarker from baseline onwards, and changes in pulmonary function (efficacy) will be explored throughout the study. the amount of glpg1837 present in the blood (pharmacokinetics) will also be determined.


Eligibility criteria:
inclusion criteria: * male or female subjects ≥ 18 years of age, with a confirmed diagnosis of cystic fibrosis * subjects with gating s1251n cftr mutation on at least one allele in the cftr gene * subjects currently receiving treatment with ivacaftor on a stable regimen or not on a treatment regimen with ivacaftor, for at least 2 weeks prior to screening * weight ≥ 40.0 kg * subjects on stable concomitant treatment regimen for at least 4 weeks prior to baseline (excluding ivacaftor) * pre- or post-bronchodilator fev1 ≥ 40% of predicted normal * subject will have to use highly effective contraceptive methods exclusion criteria: * on an ivacaftor-containing treatment regimen and unable or unwilling to discontinue ivacaftor for the washout and treatment periods of the study * concomitant use of antifungal drugs within 4 weeks of baseline * a history of a clinically meaningful unstable or uncontrolled chronic disease * liver cirrhosis and portal hypertension * any significant change in the medical regimen for pulmonary health within 4 weeks of baseline * unstable pulmonary status or respiratory tract infection or changes in therapy for pulmonary disease within 4 weeks of baseline * abnormal liver function * clinically significant abnormalities on ecg * history of malignancy, solid organ/haematological transplantation * abnormal renal function * participation in another experimental therapy study within 30 days or 5 times half-life

Keywords: cystic fibrosis s1251n mutation glpg1837
evaluation of prehabilitation as a strategy to minimize surgical risk in pancreatic surgery: efficacy and determining factors.

Conditions: Pancreatic Neoplasms; Anesthesia

Summary: several studies in major abdominal surgery demonstrated that preoperative optimization of surgical patients through prehabilitation is associated with fewer postoperative complications. however, patients' response to preoperative optimization is unpredictable, and there are no studies confirming the real benefit in pancreatic surgery. aims: to assess the benefits of pre-rehabilitation in pancreatic surgery, and identify those factors associated with an effective optimization. secondary aims: impact of prehabilitation on nutritional status, sarcopenia, quality of life, inflammation markers, postoperative complications and hospital stay compared to low-risk patients. design: an objective multimodal assessment will be performed on those patients who are candidates to pancreaticoduodenectomy (pd) to identify patients at high-risk of postoperative complications. these patients will undergo prehabilitation and response will be evaluated. intervention:multimodal prehabilitation will include: 1. physical and cardiopulmonary training followed by a personalized program according to basal aerobic capacity, patient circumstances and compliance, community-based and remote-controlled with information and communication technology (ict). 2. personalized nutrition program adapted to the underlying disease (exocrine insufficiency, cachexia and sarcopenia, diabetes). 3. treatment of anxiety and depression. subjects: 56 consecutive patients who are high-risk candidates (anaerobic threshold 11ml/kg/min at cpet) for pd recruited at hospital clinic of barcelona. postoperative variables will be compared to low-risk patients evaluated during the same study period. analysis: the main variable will be aerobic capacity (vo2max, at). secondary variables (before and after the program) will be nutritional status, sarcopenia, quality of life, inflammation markers and immune response, hospital stay, complications, 90-days mortality and costs.


Eligibility criteria:
inclusion criteria: * adult patients eligible for pancreatic surgery (pd) who are considered high risk based on the findings of the cpet (anaerobic threshold, au \<11ml/kg/min) (older p et al. crit care. 2004;8:369-72) and accepted as candidates for said surgery by the multidisciplinary committee of our institution. exclusion criteria: * non-elective surgery; * palliative surgery; * unstable respiratory or cardiac disease; * locomotor or cognitive limitations that prevent adherence to the program; * refusal to participate in the study.
a study of ro7123520 to evaluate the safety and efficacy in participants with moderately to severely active rheumatoid arthritis (ra) who are inadequately responding to anti-tumor necrosis factor (tnf)-alpha therapy

Conditions: Rheumatoid Arthritis

Summary: this is a phase iia/b double-blind, placebo-controlled, randomized, parallel group, multicenter study to evaluate the safety and efficacy of ro7123520 as adjunctive therapy in participants with ra who are inadequately responding to standard-of-care (methotrexate and anti-tnf-alpha therapy). part 1 of the study will evaluate safety. part 2 will evaluate efficacy and safety. part 3 will evaluate dose-ranging efficacy. participants will have the option of continuing to the extension period of the study.


Eligibility criteria:
inclusion criteria: * diagnosis of adult-onset ra as defined by the acr 2010 criteria, for at least 6 months before screening * moderately to severely active ra as defined by at least 4/28 tender joints and at least 4/28 swollen joints, and a das28 greater than or equal to (≥) 3.2 * for part 2 only: active synovitis and/or osteitis as determined by contrast-enhanced magnetic resonance imaging * participants must be taking stable dose of anti-tnf-alpha therapies * participants on stable oral glucocorticoids within 6 weeks of planned randomization * participants taking non-steroidal anti-inflammatory drugs (nsaids) intermittently (up to 2-3 times weekly) for short-term relief of pain and participants on regular nsaid use (on stable dose for ≥ 4 weeks) exclusion criteria: * parenteral glucocorticoids administration (intramuscular, iv) of ≥50 mg within 6 weeks or less than or equal to (≤) 50 milligrams (mg) within 4 weeks prior to planned randomization, or scheduled parenteral administrations during the study * joint(s) injected with intra-articular glucocorticoids or hyaluronic acid within 6 weeks prior to planned randomization * active inflammatory diseases of the joints not related to ra * systemic autoimmune disease other than ra * juvenile idiopathic arthritis or juvenile ra and/or ra developed before the age of 16 * active fibromyalgia that makes appropriate assessment of ra disease activity challenging in the opinion of the investigator * ra participants functional status class iv according to the acr 1991 criteria * participants with severe chronic or recurrent viral, bacterial, parasitic, or fungal infections * history of active hepatitis b virus (hbv), hepatitis c virus (hcv), or human immunodeficiency virus (hiv) infection * any identified confirmed congenital or acquired immunodeficiency * abnormal laboratory values and liver function test * myocardial infarction within less than 6 months prior to participation in the study * severe central or peripheral nervous system diseases
prophylactic analgesic and antiemetic regimen for medical abortion < 70 days

Conditions: Nausea; Pain

Summary: randomized trial which will aim to evaluate whether prophylactic use of ondansetron and ibuprofen will decrease side effects associated with medical abortion and increase patient satisfaction.


Eligibility criteria:
inclusion criteria: * healthy * english speaking * female volunteers undergoing medical abortion whether for voluntary interruption of pregnancy or missed abortion * gestational age \</= 70 days confirmed via ultrasound * access to a time keeping device * willingness to complete a telephone or in-clinic follow up exclusion criteria: * chronic medical problems including but not limited to cardiac conditions, malignancy or organ damage * failed medical abortion resulting in surgical management * known intrauterine infection * known allergy to ondansetron or ibuprofen * subjects chronically receiving analgesic drugs * subjects unable to give consent * subjects taking medications that interact with ondansetron or ibuprofen

Keywords: medical abortion prophylactic use nausea pain patient satisfaction
treatment of early knee osteoarthritis with autologous adipose-derived mesenchymal stem cells

Conditions: Knee Osteoarthritis

Summary: the purpose of this study is to explore the efficacy and safety of autologous adipose mesenchymal stem cells in the treatment of early knee arthritis. investigator believes that autologous adipose mesenchymal stem cells can relieve pain, improve knee function, promote knee cartilage regeneration and improve life satisfaction of patients.

investigators extracted abdominal fat from eight patients, extracted autologous adipose mesenchymal stem cells and injected them into the knee joint of the patients. the data were followed up regularly after operation and compared with those before operation.

Eligibility criteria:
inclusion criteria: * aged 18-65 years, male and female, patient can tolerate surgery; * clinical diagnosis of early stage degenerative arthritis by radiographic criteria and physical examination; * obviously extra-articular malformation; * course of disease ≥ six months; * no medication for knee osteoarthritis in the past three months * evaluated has not at the risk of cancer; * subjects who understand and sign the consent form for this study. exclusion criteria: * acute joint injury; * patients with severe primary diseases, such as cardiovascular,cerebrovascular, liver, kidney and hematopoietic system, and psychosis; * cancer patients; * women who are pregnant or breast feeding,or allergic constitution patient; * positive serology for hiv-1 or hiv-2, hepatitis b (hbsag, anti-hepatitis c virus -ab), hepatitis c (anti-hepatitis c virus -ab) and syphilis; * receive other open surgery related to knee operation within 6 months; * participation in another clinical trial; * failing to comply with the inclusion criteria, unwilling to comply with the research approach, or incomplete data affecting the curative effect or safety judgment.

Keywords: autologous adipose-derived mesenchymal stem cells knee osteoarthritis
evaluation of nevisense as support tool for the diagnose of keratinocyte skin cancer

Conditions: Keratinocyte Skin Cancer

Summary: this is a prospective study to assess efficacy of the nevisense device in identifying keratinocyte skin cancer (kc) in patients suspected of having skin cancer based on the initial physician's assessment. all skin lesions with a suspicion of basal cell carcinoma (bcc), invasive squamos cell carcinoma (iscc), bowen's disease (bd) or actinic keratosis (ak) and destined for excision or biopsy for further histopathological analysis will be considered for inclusion in the study.


Eligibility criteria:
inclusion criteria: * all male or female patients of any ethnicity, ≥ 18 years with skin lesions of a clinical uncertain diagnosis suspicious for kc (such as bcc, iscc, bd or ak) exclusion criteria: * metastases of recurrent lesions * lesion located on acral skin, e.g. sole or palm * lesion located on areas of scars, crusts, psoriasis or similar skin conditions * lesion on hair-covered areas, e.g. scalp, beards, moustaches * lesion located on genitalia * lesion located in an area that has been previously biopsied or subjected to any kind of surgical intervention or traumatized * lesion located on mucosal surfaces * lesion with foreign matter, e.g. tattoo or splinter * lesion and / or reference located on acute sunburn * skin surface not measurable, e.g. lesion on a stalk * skin surface not accessible, e.g. inside ears, under nails

Keywords: electrical impedance spectroscopy
efficacy and safety of xuesaitong soft capsule for coronary heart disease unstable angina

Conditions: Coronary Heart Disease; Unstable Angina

Summary: in this study, typical cases of coronary heart disease are selected. they will be intervened by xuesaitong soft capsules to investigate efficacy and safety for coronary heart disease.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of coronary angiography unstable angina * clinical diagnosis of unstable angina * age of 30 to 75 years old * not use thrombolysis, dilate coronary drugs within two weeks * sign the consent exclusion criteria: * severe valvular heart disease * insulin-dependent diabetes * mental disease * combined with severe liver, kidney, hematopoietic system disorder * patients with malignant tumors * pregnancy or breast-feeding women * recent history of trauma * drug allergy